Compositions and methods for the treatment of xerostomia

Abstract

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.

Description

[0001] priority [0002] This application claims the benefit of Indian Provisional Patent Application No. 201641033958 filed on October 4, 2016, the entire disclosure of which is incorporated by reference into this application for all purposes. technical field [0003] The present disclosure generally relates to compounds and compositions for the treatment of xerostomia. More specifically, the present invention relates to the treatment of a subject with a pharmaceutically acceptable dose of a compound, crystal, solvate, enantiomer, stereoisomer, ester, hydrate, or mixture thereof. Background technique [0004] Xerostomia is the subjective experience of dry mouth and can be associated with reduced salivary gland flow. Reduced saliva flow may in turn lead to an increased risk of oral fungal infections, dental caries, swallowing problems, and altered sense of taste. Xerostomia is a common symptom in patients with advanced cancer and has been reported in up to 77% of patients ...

AI Technical Summary

Problems solved by technology

One possible explanation is that older individuals take multiple dry medications for their chronic disease and this may lead to an overall decrease in unstimulated salivary flow

Images